Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Prognostic indicators for long-term disability in multiple sclerosis patients.
Secukinumab shines in small MS trial
Back on the scent: the olfactory system in CNS demyelinating diseases.
Naltrexone prescribing information
Leukocyte infiltration across the blood-spinal cord barrier is modulated by sleep fragmentation in mice with experimental autoimmune encephalomyelitis.
Fatigue and Depression in Children With Demyelinating Disorders.
Mortality in multiple sclerosis: meta-analysis of standardised mortality ratios.
CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation.
Low-contrast multifocal visual evoked potentials: Identifying more shades of gray in MS.
The immune balance between memory and regulatory B cells in NMO and the changes of the balance after methylprednisolone or rituximab therapy.
The anti-inflammatory effect of donepezil on experimental autoimmune encephalomyelitis in C57 BL/6 mice.
Proceedings of the European Charcot Foundation Symposium A Reappraisal of Nutrition and Environment in Multiple Sclerosis, European Charcot Foundation Symposium, December 2-4, 2010, Fiuggi, Italy.
Cognitive dysfunction in early multiple sclerosis: altered centrality derived from resting-state functional connectivity using magneto-encephalography.
Patients' experiences of adapting to multiple sclerosis: a qualitative study.
Biomarkers for multiple sclerosis.
Immunological Hallmarks of JC Virus Replication in Multiple Sclerosis Patients on Long-Term Natalizumab.
Genetic and epigenetic fine mapping of causal autoimmune disease variants.
Comparison of DNA-Hydrolyzing Antibodies from the Cerebrospinal Fluid and Serum of Patients with Multiple Sclerosis.
In multiple sclerosis oligoclonal bands connect to peripheral B cell responses.
T-cell vaccination in Crohn's disease: principles and presentation of the first two cases.
Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy.
The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study.
Laquinimod CHMP/EMA opinion
Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?
A2A Adenosine Receptor Signaling in Lymphocytes and the Central Nervous System Regulates Inflammation during Experimental Autoimmune Encephalomyelitis.

Pages